GBT Stock Overview
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD).
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Global Blood Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$68.49 |
| 52 Week High | US$73.02 |
| 52 Week Low | US$21.65 |
| Beta | 0.46 |
| 1 Month Change | 1.02% |
| 3 Month Change | 98.98% |
| 1 Year Change | 169.54% |
| 3 Year Change | 45.26% |
| 5 Year Change | 106.30% |
| Change since IPO | 58.87% |
Recent News & Updates
Global Blood Therapeutics expects to complete Pfizer deal in early October
Sep 30Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
Sep 16Recent updates
Global Blood Therapeutics expects to complete Pfizer deal in early October
Sep 30Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
Sep 16Pfizer said to have had bidding war with Johnson & Johnson for Global Blood
Aug 24What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics
Aug 08Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil
Jul 14GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease
Jun 29Global Blood Therapeutics: Powerhouse Of The Future
Jun 21Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt
Jun 07
Global Blood Therapeutics: Hitting A Growth Inflection
Apr 12Global Blood Therapeutics: Changing My Strategy After Recent Earnings
Mar 12Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?
Feb 24Global Blood Therapeutics: Revisiting A Stellar Grower
Dec 25IBI Research On Global Blood Therapeutics: Galvanized For Growth
Nov 30Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt
Nov 03Global Blood Therapeutics: It Might Be Time To Buy The Dip
Oct 24Global Blood Therapeutics: Attempting To Classify The Investment
Aug 07Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jul 08Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why
Jun 12Global Blood Therapeutics announces employment inducement grants
Jun 04Global Blood Therapeutics: Increasing Specialization In SCD
May 09Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?
Mar 18Breakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Feb 20
Did Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?
Jan 25Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares?
Dec 29Health Check: How Prudently Does Global Blood Therapeutics (NASDAQ:GBT) Use Debt?
Dec 03Shareholder Returns
| GBT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.6% | -4.7% | -3.7% |
| 1Y | 169.5% | -2.7% | 20.2% |
Return vs Industry: GBT exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: GBT exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| GBT volatility | |
|---|---|
| GBT Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GBT's share price has been volatile over the past 3 months.
Volatility Over Time: GBT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 457 | Ted Love | www.gbt.com |
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
Global Blood Therapeutics, Inc. Fundamentals Summary
| GBT fundamental statistics | |
|---|---|
| Market cap | US$4.62b |
| Earnings (TTM) | -US$322.46m |
| Revenue (TTM) | US$234.86m |
19.7x
P/S Ratio-14.3x
P/E RatioIs GBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GBT income statement (TTM) | |
|---|---|
| Revenue | US$234.86m |
| Cost of Revenue | US$4.45m |
| Gross Profit | US$230.41m |
| Other Expenses | US$552.87m |
| Earnings | -US$322.46m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.78 |
| Gross Margin | 98.10% |
| Net Profit Margin | -137.30% |
| Debt/Equity Ratio | 491.7% |
How did GBT perform over the long term?
See historical performance and comparison